HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
ConditionHuman Papilloma Virus
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age6-75
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
Eligibility criteria
Qualifiers
Written, informed consent obtained prior to any study-specific procedures.
Evidence of HPV virus activation (viral DNA) or high risk of HPV infection.
Not suitable for routine treatment or invalid to antiviral drugs.
Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA.
Disqualifiers
Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.
Subject is albumin-intolerant.
Subject with life expectancy less than 8 weeks.
Subject participated in other investigational somatic cell therapies within past 30 days.
Trial design
Treatments tested in this trial
- HPV-CTLs
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov